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Abstract
Pandemic (H1N1) 2009 influenza virus spread throughout the world since most people did not have immunity against
the virus. In the post pandemic phase when many humans might possess immunity against the pandemic virus, one
of the concerns is infection in immunocompromised people. Therefore, we used an immunosuppressed macaque
model to examine pathogenicity of the pandemic (H1N1) 2009 virus under an immunocompromised condition. The
virus in nasal samples of immunosuppressed macaques infected with the pandemic (H1N1) 2009 virus was detected
longer after infection than was the virus in nasal samples of immunocompetent macaques. As expected, not only
virus amounts but also virus propagation sites in the immunosuppressed macaques were larger than those in lungs
of the immunocompetent macaques when they were infected with the pandemic virus. Immunosuppressed
macaques possessed low levels of immune cells producing cytokines and chemokines, but levels of inflammatory
cytokines/chemokine interleukin (IL)-6, IL-18, and monocyte chemotactic protein (MCP)-1 in lungs of the
immunosuppressed macaques were higher than those in lungs of the immunocompetent macaques, though the
differences were not statistically significant. Therefore, under an immunosuppressive condition, the pandemic
influenza (H1N1) 2009 virus might cause more severe morbidity with high cytokine/chemokine production by the host
innate immune system than that seen in macaques under the immunocompetent condition.
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Introduction
A pandemic H1N1 influenza virus emerged and spread
throughout the world in 2009 [1]. Most of the people except for
those born before 1918 might have been susceptible to the
pandemic (H1N1) 2009 virus because of the lack of a
neutralization antibody against the virus [2]. The pandemic
(H1N1) 2009 virus also caused severe pneumonia since it was
shown that the pandemic virus propagated more vigorously
than did a seasonal influenza virus (Russian flu virus) in the
lungs of animal models and human patients [2-6]. After the
World Health Organization declared a postpandemic phase in
August 2010 (http://www.who.int/mediacentre/news/
statements/2010/h1n1_vpc_20100810/en/index.html) [7], the
pandemic (H1N1) 2009 influenza virus has been recognized as
a seasonal influenza virus. Although several variations in a
hemagglutinin (HA) protein in the pandemic (H1N1) 2009
influenza virus and its descendent virus have been reported
[8,9], no remarkable variations that required change of a
vaccine strain have been reported as of the 2012-2013 season
[10,11] (http://www.who.int/influenza/vaccines/virus/
candidates_reagents/summary_a_h1n1_cvv_20120308.pdf).
Therefore, antigenicity of the pandemic (H1N1) 2009 virus
seems to have been maintained even after it became a
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seasonal influenza virus. Since many people might possess
immunity against the pandemic strain due to infection and
vaccination after 2009, we need to pay further attention to
immunocompromised people as well as elderly and young
people who have low levels of immune responses against the
virus.
Non-human primates have been used to extrapolate
pathogenicity of various pathogens in humans. We reported
that the pandemic (H1N1) 2009 virus propagated in the lungs
of immunologically naïve macaques more vigorously than did
the seasonal Russian flu virus [2]. Indeed, viral pneumonia
caused by the pandemic (H1N1) 2009 virus was reported in
humans during the pandemic. Immunosuppression altered
morbidity induced by pathogens in macaques. For example, in
simian immunodeficiency virus (SIV) infection models,
microsporidia infection might contribute to morbidity [12] as
reported in humans [13]. Irradiation, another method to induce
immunosuppression, made rhesus macaques susceptible to
methicillin-resistant Staphylococcus [14] as was reported in
humans [15]. After transplantation and immunosuppression,
simian parvovirus infection caused severe anemia in
cynomolgus monkeys [16] as reported in humans, in which
parvovirus infection usually caused erythema infectiosum (fifth
disease) in childhood [17,18]. In addition, immunosuppression
allowed pathogens to spread systemically. Neurotropic SV40
spread through the blood to other organs in SIV-infected
macaques [19] as was human JC virus detected in blood and
urine samples of human immunodeficiency virus (HIV)-infected
patients [20]. Treatment of macaques with anti-thymocyte
globulin, cyclophosphamide, and cortisone acetate caused a
systemic active cytomegalovirus (CMV) infection [21].
Therefore, immunosuppression made pathogens proliferate
and spread to unusual propagation sites, resulting in increase
of pathogenicity in macaques as well as humans.
To reveal the pathogenicity of influenza virus in
immunocompromised hosts compared to that in
immunocompetent hosts, we used an immunosuppressed
macaque model and examined symptoms and virus
propagation. We also compared pathogenicity of pandemic
(H1N1) 2009 influenza virus to that of the seasonal H1N1
influenza virus isolated in 2007 (Russian flu virus) in
immunosuppressed macaques. Our immunosuppressive
protocol decreased the concentration of white blood cells,
especially lymphocytes in peripheral blood, and inhibited
interleukin-2 (IL-2) responses of lymphocytes. Under the
immunosuppressed condition, propagation of pandemic (H1N1)
2009 and Russian flu viruses in the respiratory tract was
prolonged compared to that under the immunocompetent
condition. Furthermore, Russian flu virus was detected in the
lungs of immunosuppressed macaques but not in the lungs of
immunocompetent macaques. Even under the
immunocompromised condition, levels of cytokine production 7
days after infection in the lungs of immunosuppressed
macaques were higher than those in the lungs of
immunocompetent macaques. These results suggest that
immunosuppressive treatment to inhibit inflammation might not
necessarily ameliorate hypercytokinemia and symptoms in
influenza virus infection.
Results
Immunosuppression by cyclophosphamide and
cyclosporine A in cynomolgus macaques
To establish a protocol for suppressing the immune system
in cynomolgus macaques, we firstly counted white blood cell
numbers in blood as a biomarker for effective
immunosuppression (i.e., leukocytopenia). According to
previous studies [22-25], we compared two regimens, high-
dose and low-dose cyclophosphamide (CP) treatment with
cyclosporine A (CA) (Table 1). The concentrations of CA in
plasma of macaques treated with high-dose and low-dose CP
on day 6 were 65 and 23 ng/ml, respectively. In the blood of a
macaque treated with the low dose regimen, the white blood
cell count was decreased 7 days after the beginning of
suppressive treatment and it partially recovered on day 12 (5
days after the end of treatment), whereas in the high dose
regimen, decrease in white blood cell count continued until day
14 (7 days after the end of treatment) (Figure 1A).
Next, we examined the population of white blood cells using
a flow cytometer. Lymphocytes (R1), monocytes (R2), and
granulocytes (R3) were identified on the basis of forward and
side scatters (Figure 1B, C, Figure S1). In the blood of the
macaque treated with the low dose regimen, the percentage of
lymphocytes (R1), especially CD8+ cells, was decreased
instead of increase of granulocyte ratios and the percentage of
lymphocytes was recovered on day 10 (3 days after the end of
treatment) (Figure 1B, D, Figure S1A). In the high dose
regimen, the percentage of lymphocytes (R1), especially CD8+
cells, and the percentage of CD14+ cells in monocyte
population (R2) were decreased on day 6 (Figure 1C, E, Figure
S1B). The decrease in number of lymphocytes did not recover
until the end of the observation period in the high dose regimen
(Figure 1C).
Since CA inhibits the function of calcineurin, resulting in
induction of anergy in T lymphocytes [26,27], we measured
IL-2 production by mononuclear cells with either phorbol 12-
myristate 13-acetate (PMA) + ionomycin (Figure 1F) or anti-
CD3 + anti-CD28 + anti-CD49d stimulation (Figure 1G). In both
regimens, IL-2 production by stimulated leukocytes and T
Table 1. Immunosuppression protocol before influenza
virus infection.
Days after suppression1 Low dose regimen High dose regimen
 CP2 (mg/kg) CA2 (mg/kg) CP (mg/kg) CA (mg/kg)
0 20 50 40 50
1 -2 50 - 50
2 20 50 40 50
3 - 50 - 50
4 20 50 40 50
5 - 50 - 50
6 20 50 40 50
1 Days after the beginning of suppression used in Figure 1.
2 CP: cyclophosphamide, CA: cyclosporine A. - without administration.
doi: 10.1371/journal.pone.0075910.t001
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Figure 1.  Blood cell population and IL-2 production after immunosuppression.  Peripheral blood was collected on the
indicated days after the first administration of CP and CA. (A) The number of white blood cells was counted using a microscope and
a hemocytometer. (B, C) The percentage of white blood cell population was calculated on the basis of forward and side scatter
scales (FSC and SSC) in flow cytometric analysis. Representative profiles of flow cytometric results are shown in Figure S1.
Lymphocytes, monocytes, and granulocytes were determined as populations in R1 (low FSC/low SSC), R2 (high FSC/low SSC),
and R3 (high FSC/high SSC), respectively. (D, E) The percentages of CD4+, CD8+, CD20+, and CD14+ cells were determined with a
flow cytometer. The percentages of CD4+, CD8+, and CD20+ cells are indicated as the percentages in R1. The percentages of
CD14+ cells are indicated as the percentages in R2. B, D: a monkey treated with low CP and CA, C, E: a monkey treated with high
CP and CA. (F, G) Peripheral blood cells were culture with PMA+ionomycin (F) or anti-CD3 + anti-CD28 + anti-CD49d antibody (G)
for 24 h. IL-2 in supernatants was measured with ELISA. Results are shown as averages of triplicate cultures except asterisked
points in which results were calculated from less than three wells since sufficient cells to make triplicate cultures were not collected.
doi: 10.1371/journal.pone.0075910.g001
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lymphocytes was severely down-regulated after administration
of immunosuppressive agents, though IL-2 secretion recovered
after discontinuation of the drugs, especially in the low dose
regimen. These results indicated that the high dose regimen
was required for suppression and maintenance of
immunosuppression during the experiments.
Influenza Virus Replication in Immunocompromised
Macaques
To examine the pathogenicity of influenza virus in
immunosuppressed macaques, we administered CP and CA in
the high dose regimen as determined above (Table 2) and then
inoculated the macaques with seasonal Russian influenza virus
A/Yokohama/91/2007 (H1N1) (YOK91) or pandemic influenza
virus A/Narita/1/2009 (H1N1) (NRT1) into the nostrils, oral
cavity, and trachea. All macaques except one (N6), in which
the transmitter lost electric power to record, showed higher
body temperature than that before infection (Figure S2) even
when white blood cell counts were decreased in macaques
treated with CP and CA (Figure 2). In macaques inoculated
with YOK91 (Y1) and NRT1 (N1 and N2) without
immunosuppression, the number of lymphocytes and
granulocytes temporally decreased after virus inoculation
(Figure S3). These results suggested that high body
temperature (fever) after viral infection might not be necessarily
dependent on responses of white blood cells.
The virus was detected in nasal samples of all three
macaques without immunosuppression challenged with
seasonal virus YOK91 until up to day 5 after infection, whereas
the virus was detected in nasal samples of two
immunosuppressed macaques (Y5, Y6) until day 7 and in
tracheal and bronchial samples until day 6 in one of the
immunosuppressed macaques (Y5) (Figure 3A-C). A
comparison of the immunosufficient and immunosuppressed
macaques inoculated with NRT1 showed that virus titers in
nasal samples of the immunosuppressed macaques on day 7
were significantly higher than those in nasal samples of
immunocompetent macaques (P = 0.046 by Student’s t-test,
Figure 3D). These results showed that immunosuppression
Table 2. Immunosuppression protocol for influenza virus
infection.
Days after infection1 CP2 (mg/kg) CA2 (mg/kg)
-7 40 50
-6 -2 50
-5 40 50
-4 - 50
-3 40 50
-2 - 50
-1 40 50
0 - 50
1 Days used in experiments with virus infection.
2 CP: cyclophosphamide, CA: cyclosporine A, - without administration.
doi: 10.1371/journal.pone.0075910.t002
enhanced propagation of pandemic (H1N1) 2009 virus in nasal
swab samples.
We calculated the areas under the virus titer curves (virus
titer AUCs) to compare overall virus propagation. Significant
differences on average virus titer AUCs in nasal, tracheal, and
bronchial samples were observed between the macaques
inoculated with YOK91 and those inoculated with NRT1 without
immunosuppression (Figure 3G-I, P < 0.05 by Student’s t-test).
These results confirmed that the pandemic (H1N1) 2009 virus
replicated in macaques more vigorously than did the seasonal
Russian flu virus as previously reported [2]. However, virus titer
AUCs in the tracheal and bronchial samples of
immunosuppressed macaques infected with NRT1 were
smaller than those in the samples of immunocompetent
macaques (Figure 3H, I).
In tissue samples collected at autopsy 7 days after virus
inoculation, virus was under the detection limit in all of the
immunocompetent macaques infected with YOK91 (Figure 4A).
On the other hand, the virus was detected in the upper airway
of two immunosuppressed macaques (Y5, Y6) and in one to
four lobes of lungs of all immunosuppressed macaques (Y4-
Y6). Pandemic virus was detected in oronasopharynx mucosa
(N1, N3), a tonsil (N2), trachea (N2), bronchi (N1, N2), and two
lobes of the lung (N1) of immunocompetent macaques
inoculated with NRT1 (Figure 4B). On the other hand, high
titers of pandemic virus were detected in oronasopharynx
Figure 2.  White blood cell counts in peripheral blood after
immunosuppression.  Total white blood cells were counted
using a microscope and a hemocytometer. (A) Macaques
infected with seasonal influenza virus A/Yokohama/91/2007
(H1N1) (YOK91) on day 0. (B) Macaques infected with
pandemic influenza virus A/Narita/1/2009 (H1N1) (NRT1) on
day 0. Red lines: macaques administered saline from day -7 to
day 0. Blue lines: macaques administered CP and CA from day
-7 to day 0.
doi: 10.1371/journal.pone.0075910.g002
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mucosa (N4), a tonsil (N4), trachea (N5, N6), bilateral bronchi
(N4), six lobes of the lung (N4), and two lobes of the lung (N5)
in three immunosuppressed macaques. No virus was detected
in other organs of immunocompromised macaques infected
with YOK91, whereas the pandemic virus was detected in one
of two tissue pieces of the cerebellum (2.00 log10TCID50/g),
ileum (1.67 log10TCID50/g), colon (1.67 log10TCID50/g), and
urinary bladder (1.67 log10TCID50/g) samples in the N4
macaque, and colon (1.67 log10TCID50/g) in the N6 macaque
when we collected two pieces of tissue samples from each
organ. The presence of virus was confirmed by
immunohistochemical staining of nucleoprotein (NP) in a small
number of type I and type II alveolar epithelial cells in the lung
of an immunosuppressed macaque infected with YOK1 (Y4),
but not in the lung of an immunocompetent macaque infected
with YOK1 (Y3) (Figure S4B, C). NP was detected in
Figure 3.  Virus recovery in swab samples from macaques administered immunosuppressive agents.  Cynomolgus
macaques were administered CP and CA (blue lines) or saline (red lines) from day -7 to day 0 as shown in Table 2 and then
inoculated with YOK91 (A-C) or NRT1 (D-F) on day 0. Viral titers in nasal (A, D), tracheal (B, E), and bronchial (C, F) samples were
determined using MDCK cells. Virus titers under the detection limit (< 0.67 TCID50/ml) are indicated as 0. (G-I) Virus titer areas
under the virus titer time curves (virus titer AUC) in nasal (G), tracheal (H), and bronchial (I) samples were calculated on the basis of
titers in A-F. Averages and standard deviations of three macaques are shown in each group. Asterisks indicate significant
differences (P < 0.05, Student’s t-test).
doi: 10.1371/journal.pone.0075910.g003
Influenza Infection in Immunosuppressed Macaques
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bronchiolar epithelial cells in the lung of an immunocompetent
macaque infected with NRT1 (Figure S4D), whereas many type
II alveolar epithelial cells and a few bronchiolar epithelial cells
were positive for NP in the lungs of immunosuppressed
macaques infected with NRT1, N4 and N5, respectively (Table
3). The number of cells positive for NP antigen in the
immunohistochemically stained sections was compatible with
virus titers in lungs, especially in the lung of N4. No NP antigen
was detected in the cerebellum, urinary bladder, and colon of
N4 probably due to a low antigen concentration (Figure S4F-
H). These results indicate higher propagation activity of the
pandemic (H1N1) 2009 virus than that of the seasonal Russian
flu virus as previously reported [2] and also indicate that
immunosuppression enhanced dissemination of both seasonal
and pandemic viruses.
Inflammatory responses in immunosuppressed
macaques after influenza virus infection
We examined inflammatory responses in the macaques with
or without immunosuppression after infection. Cytokine
production was examined in lung tissues excised 7 days after
virus infection (Figure 5). Levels of tumor necrosis factor
(TNF)-α and IL-1β production in the lungs were low in
macaques with or without immunosuppression. Although no
statistically significant differences were found, concentrations
of interferon (IFN)-β, IL-18, and monocyte chemotactic protein
(MCP)-1 in lungs of the immunosuppressed macaques infected
with YOK91 were higher on average than those in lungs of the
immunocompetent macaques infected with YOK91. Average
levels of IL-18, IL-6, and MCP-1 production in lungs of the
immunosuppressed macaques infected with pandemic NRT1
were higher than those in lungs of the immunocompetent
macaques infected with NRT1. On the other hand, transforming
growth factor (TGF)-β1 production in lungs of the
immunocompetent macaques infected with NRT1 was greater
than that in lungs of the immunosuppressed macaques.
Therefore, the immunosuppressed macaques showed a
Table 3. Semiquantitative analysis of virus infected cells
with immunohistochemical staining.
Virus YOK NRT NRT
Suppression + - +
Animal Y4 Y5 Y6 N1 N2 N3 N4 N5 N6
Oronasopharynx   - -  - -   
Tonsil   -  -  -   
Trachea  -   -  - - -
Bronchus   - - -  - -  
Lung + -  +*   +/++ +*  
LN chest        -  
Cerebellum       -   
Colon       -   
Urinary bladder       -   
- no virus antigen-positive cells, + some virus antigen-positive cells, ++ many virus
antigen-positive cells, +* virus antigen positive in bronchiolar epithelial cells in
lungs. Blank: not tested.
doi: 10.1371/journal.pone.0075910.t003
Figure 4.  Virus recovery in organ samples from macaques administered immunosuppressive agents.  Each macaque was
inoculated with saline (Y1-Y3, N1-N3) or immunosuppressive agents (Y4-Y6, N4-N6) as described in the legend for Figure 3.
Macaques were inoculated with YOK91 (A, Y1-Y6) or NRT1 (B, N1-N6) on day 0. Tissue samples were collected at autopsy 7 days
after virus inoculation. Tissue homogenates were prepared as 10% w/v solution. Virus titers under the detection limit (<
1.67TCID50/g tissue) are indicated as 0. R: right, L: left, RU: right upper lobe, RM: right middle lobe, RL: right lower lobe, LU: left
upper lobe, LM: left middle lobe, LL: left lower lobe, LN chest: lymph nodes in the mediastinum.
doi: 10.1371/journal.pone.0075910.g004
Influenza Infection in Immunosuppressed Macaques
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tendency to produce relatively high levels of inflammatory
cytokines and a chemokine in the lungs after infection with both
viruses and to suppress anti-inflammatory TGF-β1 production
in the case of pandemic (H1N1) 2009 virus infection, compared
to the immunocompetent macaques.
We histologically examined lung tissues 7 days after
infection. Without immunosuppression, congestion in lungs of
the macaques infected with NRT1 and YOK91 was
macroscopically observed (Figure 6A, B). Microscopically, both
NRT1 and YOK91 induced severe lymphoid infiltration in the
septum and alveolar space, resulting in thickening of alveolar
walls (Figure 6A, B), and air content in the alveoli was
decreased, especially in the lung of the immunocompetent
macaque infected with NRT1 (Figure 6B). These results were
compatible with alveolar and interstitial pneumonia. In the
immunosuppressed macaques infected with YOK91 or NRT1,
mild and local congestion in the lung was macroscopically
observed (Figure 6C, D). Microscopically, lymphocyte
infiltration into the septum and alveoli of the lung of the
macaque infected with YOK91 was minimal (Figure 6C). In the
lung of the macaque infected with NRT1, a small number of
lymphocytes and macrophages infiltrated into alveoli but not in
the septum (Figure 6D). Therefore, lymphocyte and leukocyte
responses in the immunosuppressed macaques infected with
YOK91 or NRT1 were less severe than those in the
immunocompetent macaques, but inflammatory cytokine
responses in lungs of the immunosuppressed macaques were
more vigorous than those in the immunocompetent macaques
(Figure 5).
Discussion
In the present study, we revealed that the pandemic (H1N1)
2009 virus and the seasonal Russian flu virus propagated in
immunosuppressed macaques and that inflammatory cytokines
and chemokines were produced in lungs of macaques treated
with CP and CA. The Russian flu virus was detected not only in
the upper airway but also in the lower airway under the
immunosuppressed condition. The pandemic (H1N1) 2009
virus was detected in both the upper and lower airways without
immunosuppression, and higher virus titers in the lungs were
detected in immunosuppressed macaques than in
immunocompetent macaques. In addition, the pandemic
(H1N1) 2009 virus was detected in non-respiratory organs of
immunosuppressed macaques. These results indicated that a
high level of virus propagation inducing cytokine production
was related to severe morbidity in immunosuppressed
macaques, that immunosuppression allowed the virus to
spread to organs other than the main propagation sites in
immunocompetent macaques and that non-highly pathogenic
influenza virus systemically replicated under the
immunocompromised condition.
In immunosuppressed macaques infected with either virus,
infiltration of leukocytes was minimal in the lungs and
congestive edema was observed in alveoli probably due to
cytokines and chemokines. Therefore, we speculated that virus
in the lungs of immunosuppressed macaques might induce
inflammatory cytokine/chemokine production by non-
leukocytes, i.e., alveolar epithelial cells or stromal cells [28-31],
though we could not identify cytokine-positive cells by our
immunohistochemical staining (data not shown). Furthermore,
Figure 5.  Cytokine production after virus infection in immunosuppressed macaques.  Cytokine production in lung tissues
was measured. Averages and standard deviations of three macaques are shown. Red bars: without immunosuppression, blue bars:
with immunosuppression.
doi: 10.1371/journal.pone.0075910.g005
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if the pandemic (H1N1) 2009 virus was inhaled into the trachea
and alveoli in immunocompromised hosts, the virus would
propagate widely in the lungs and possibly other organs with
higher virus titers than would seasonal Russian flu virus and it
would induce a high level of IL-6 production, which causes
morbidity [32]. As association of IL-6 and IL-1β levels with fever
was shown in previous studies [33,34], the high temperature in
immunosuppressed macaques, especially in the N4 macaque
showing prolonged high body temperature (Figure S2), was
thought to be related to the relatively high level of inflammatory
cytokine production. In addition, weak TGF-β responses in the
pandemic (H1N1) 2009 virus infection might enhance effects of
inflammatory cytokines [35,36]. Therefore, it was thought that
pathogenicity of the pandemic (H1N1) 2009 virus was higher
Figure 6.  Histological analysis of viral pneumonia in immunosuppressed macaques.  Macaques were autopsied 7 days after
virus infection. Lung tissues were stained with hematoxylin and eosin (H & E) and representative figures are shown. (A) A macaque,
Y3, infected with YOK91 without immunosuppression, (B) A macaque, N2, infected with NRT1 without immunosuppression, (C) A
macaque, Y4, infected with YOK91 with immunosuppression, (D) A macaque, N4, infected with NRT1 with immunosuppression.
Bars in microscopic photos indicate 100 µm.
doi: 10.1371/journal.pone.0075910.g006
Influenza Infection in Immunosuppressed Macaques
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than that of the seasonal Russian flu virus under the
immunocompromised condition as well as immunocompetent
condition.
Although virus titers in nasal samples of the
immunosuppressed macaques on day 7 after pandemic
(H1N1) 2009 virus inoculation were significantly higher than
those in nasal samples of the immunocompetent macaques,
the virus titer AUCs in the trachea and bronchus of macaques
infected with the pandemic virus under the immunosuppressive
condition were lower than those in the trachea and bronchus of
macaques without immunosuppression as shown in Figure 3.
Lower virus titers in the trachea and bronchus of
immunosuppressed macaques might be caused by the
inhibitory effect of CA on influenza virus replication [37].
However, no difference in virus titer AUCs in nasal swab
samples of macaques infected with the pandemic virus was
found, and the pandemic virus was detected in more tissues of
the immunosuppressed macaques than in tissues of the
immunocompetent macaques (Figure 4B). In mouse models
infected with H3N2 and WSN virus, virus titers in lungs of mice
treated with CA as well as those in lungs of mice treated with
CP alone were higher than those in lungs of mice without CA
treatment [38-40]. Furthermore, the concentrations of CA in
plasma of macaques (Y4-Y6 and N4-N6) on day 0 (blood was
collected before infection on the day of infection) were lower
than 20 ng/ml (the detection limit), which was lower than the
concentration showing inhibition of virus propagation in vitro
[37]. Taken together, the results indicate that the effect of CA
on viral propagation was minimal at the concentration in the
present study and CA did not decrease morbidity caused by
the pandemic (H1N1) 2009 influenza.
CA and CP are widely used for prevention of rejection in
organ transplantations and treatments for cancers [41]. In
patients under the treatment with the immunosuppressive
drugs, pneumonia and mortality was reported more frequently
than in non-immunosuppressed individuals during the
pandemic in 2009 [42,43]. Furthermore, antibody responses by
influenza virus vaccination in breast cancer patients treated
with CP [44] and renal and lung transplant patients treated with
CA [45,46] were impaired. In liver transplant patients treated
with CA [47], T cell responses against vaccine antigens were
impaired as shown in the present study. Therefore, our
immunosuppressive macaques model would be used for
extrapolation of pathogenicity and development of effective
vaccination in immunocompromised patients.
Based on these features, the immunosuppressed macaque
model would be also useful for evaluating the emergence of
drug-resistant strains during treatment, such strains having
been reported in immunocompromised patients [48,49]. Since
acquired immune responses including antibody responses
should be weak in immunocompromised hosts, anti-viral drugs
might become a predominant selective pressure under an
immunosuppressed condition. Therefore, if drug-resistant
strains with mutations were detected in the immunosuppressed
macaques treated with the anti-viral drug, we could focus
surveillance using samples isolated from humans on the
predicted positions in viral proteins of drug-resistant strains.
Inflammatory responses observed in immunosuppressed
macaques infected with the virus appeared to be contradictory
to the immunocompromised condition. It has been reported that
lipopolysaccharide (LPS)-induced fever was independent of
prostaglandin E2, suggesting that fever dependent on toll-like
receptor (TLR) signals, e.g. TLR7, having been shown to be a
receptor for virus RNA [50], might not be inhibited by
cyclooxygenase (COX)-2 inhibitors or non-steroid anti-
inflammatory drugs [51]. Furthermore, corticosteroid therapy in
patients with pandemic (H1N1) 2009 virus infection was shown
to be associated with higher mortality than that without steroid
treatment [52], suggesting that corticosteroid therapy might be
hazardous as shown in mice infected with H5N1 highly
pathogenic avian influenza virus [53]. These results suggest
that anti-inflammatory drugs broadly used in humans do not
necessarily suppress inflammation and the cytokine storm
(hypercytokinemia) [54]. Therefore, development of other types
of anti-hypercytokinemia treatment rather than anti-
inflammatory drugs is required for immunocompromised
patients with influenza virus infection and for patients with
highly pathogenic avian influenza virus infection [55,56]. We
will analyze the pathogenicity of highly pathogenic avian
influenza virus and anti-hypercytokinemia treatment in
immunocompromised macaques in the future.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
Guidelines for the Husbandry and Management of Laboratory
Animals of the Research Center for Animal Life Science at
Shiga University of Medical Science and Standards Relating to
the Care and Management, etc. of Experimental Animals
(Notification No. 6, March 27, 1980 of the Prime Minister’s
Office, Japan). The protocol was approved by the Shiga
University of Medical Science Animal Experiment Committee
(Permit numbers: 2009-8-6H and 2010-10-1). The Research
Center for Animal Life Science at Shiga University of Medical
Science has a permit for importation of cynomolgus macaques.
Regular veterinary care and monitoring, balanced nutrition and
environmental enrichment were provided by the Research
Center for Animal Life Science at Shiga University of Medical
Science. The macaques were euthanized at endpoint on 7
days after virus inoculation using ketamine/xylazine followed by
intravenous injection of pentobarbital (200 mg/kg). Animals
were monitored every day during the study to be clinically
scored as described in Table S1 [57] and to undergo veterinary
examinations to help alleviate suffering. Animals would be
euthanized if their clinical scores reached 15 (a humane
endpoint) though no animals showed symptoms scored as 15
in the present study.
Animals
Five- to seven-year-old female cynomolgus macaques from
Vietnam and the Philippines (Ina Research Inc., Ina, Japan)
were used. The cynomolgus macaques used in the present
study were healthy young adults. All procedures were
performed under ketamine and xylazine anesthesia, and all
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efforts were made to minimize suffering. Food pellets of CMK-2
(CLEA Japan, Inc., Tokyo, Japan) were provided once a day
after recovery from anesthesia and drinking water was
available ad libitum. Animals were singly housed in the cages
equipping bars to climb up and puzzle feeders for
environmental enrichment under controlled conditions of
humidity (40 ± 5%), temperature (25 ± 1°C), and light (12-h
light/12-h dark cycle, lights on at 8: 00 A.M.). In the text and
figures, individual macaques are distinguished by the following
abbreviations: Y1, Y2, Y3 for macaques inoculated with YOK91
without immunosuppression, Y4, Y5, Y6 for macaques
inoculated with YOK91 with immunosuppression, N1, N2, N3
for macaques inoculated with NRT1 without
immunosuppression, and N4, N5, N6 for macaques inoculated
with NRT1 with immunosuppression. The absence of influenza
A virus nucleoprotein-specific antibodies in their sera was
confirmed before experiments using an antigen-specific
enzyme-linked immunosorbent assay (ELISA), AniGen AIV Ab
ELISA (Animal Genetics Inc., Kyonggi-do, Korea), for currently
circulating influenza virus. Two weeks before virus inoculation,
a telemetry probe (TA10CTA-D70, Data Sciences International,
St. Paul, MN) was implanted in the peritoneal cavity of each
macaque under ketamine/xylazine anesthesia followed by
isoflurane inhalation to monitor body temperature. Antibiotics
and analgesics were used after the surgery. The macaques
used in this study were free from B virus, hepatitis E virus,
Mycobacterium tuberculosis, Shigella spp., Salmonella spp.,
and Entamoeba histolytica. All experiments using viruses were
performed in the biosafety level 3 facility of the Research
Center for Animal Life Science, Shiga University of Medical
Science. Virus (3 × 106TCID50/7ml) was inoculated into nostrils
(0.5 ml for each nostril), oral cavity (0.5 ml for the surface of
each tonsil), and trachea (5 ml). Under ketamine/xylazine
anesthesia, 2 cotton sticks (TE8201, Eiken Chemical, Ltd.,
Tokyo, Japan) were used to collect fluid samples in nasal
cavities and tracheas, and the sticks were subsequently
immersed in 1 ml of phosphate-buffered saline (PBS)
containing 0.1% bovine serum albumin (BSA) and antibiotics. A
bronchoscope (MEV-2560, Machida Endoscope Co. Ltd.,
Tokyo, Japan) and cytology brushes (BC-203D-2006, Olympus
Co., Tokyo, Japan) were used to obtain bronchial samples. The
brushes were immersed in 1 ml PBS with BSA.
Viruses
The seasonal influenza virus A/Yokohama/91/2007 (H1N1)
(kindly provided by Dr. Chiharu Kawakami, Yokohama City
Institute. National Center for Biotechnology Information (NCBI)
taxonomy database ID: 568510) was propagated in Madin-
Darby canine kidney (MDCK) cells twice at Yokohama City
Institute and once in MDCK cells at Shiga University of Medical
Science [58]. The pandemic influenza virus A/Narita/1/2009
(H1N1) pdm (kindly provided by Dr. Takato Odagiri, National
Institute of Infectious Disease (NIID), Japan. NCBI taxonomy
database ID: 645520) [59,60] was cultured twice in
embryonated eggs in NIID and once in MDCK cells at Shiga
University of Medical Sciences.
In order to assess virus replication, serial dilutions of swab
samples and homogenized tissue samples were inoculated
onto confluent MDCK cells as described previously [61].
Cytopathic effects were examined under a microscope 72 h
later.
Immunosuppressive treatment
Cyclophosphamide (Nakalai Tesque, Kyoto, Japan) was
dissolved in saline (Otsuka Pharmaceutical Co., Ltd.,
Tokushima, Japan) at 40 mg/ml, stored at 4 °C after filtration,
and used within 2 days of preparation. CP was intravenously
administered by bolus injection. Cyclosporine A (Novartis
Pharma, Basel, Switzerland, 100 mg/ml) was orally
administered by catheters. The concentration of CA in plasma
was measured by SRL Inc., Tokyo, Japan, with a double-
antibody radioimmunoassay method.
Blood cells
The numbers of leukocytes in blood were counted using a
hemocytometer and a microscope. For flow cytometry, whole
blood cells were stained with phycoerythrin (PE)-conjugated
anti-CD8 (clone: SK1, eBioscience, San Diego, CA),
allophycocyanin (APC)-conjugated anti-CD4 (clone: OKT-4,
eBioscience), FITC-conjugated anti-CD14 (clone: M5B2,
BioLegend, Inc., San Diego, CA), and PE-conjugated anti-
CD20 (clone: 2H7, BioLegend). Dead cells were excluded by
staining with ethidium monoacetate (EMA, Molecular Probes,
Inc., Eugene, OR). Red blood cells were lysed with tris-
ammonium chloride. Cells were fixed with PBS containing 4%
paraformaldehyde before flow cytometer analysis.
Cytokine assay
In the experiment for which results are shown in Figure 1,
white blood cells were purified from 2 ml of peripheral blood
using a density gradient (Wako Pure Chemical Industries Ltd.,
Osaka, Japan). After washing twice, 1 × 105 cells were cultured
with anti-CD3 (clone: SP34), anti-CD28 (clone: CD28.2) and
anti-CD49d (clone: 9F10) antibodies (0.5 µg/ml, eBioscience)
or with phorbol 12-myristate 13-acetate (PMA) (0.1 µg/ml,
Nacalai Tesque) and ionomycin (1 µg/ml, Nacalai Tesque) in
96-well U-bottom plates for 24 h and supernatants were
collected. The concentrations of IL-2 in culture supernatants
were determined using MAX Deluxe SET Human IL-2
(BioLegend).
In the experiment for which results are shown in Figure 5,
lung tissues obtained at autopsy on day 7 after the challenge
infection were used after homogenization. Tissue homogenates
were prepared as 10% w/v solution. The concentrations of IFN-
β and total TGF-β1 were measured using the VeriKineTM
Human Interferon Beta ELISA kit (Pistka Biomedical
Laboratories, Inc., PBL Interferon Source, Piscataway, NJ) and
the human TGF-β1 ELISA kit (R&D Systems, Inc., Minneapolis,
MN), respectively. The concentrations of TNF-α, IL-1β, IL-6,
IL-18, and MCP-1 in homogenates were measured using the
Milliplex MAP non-human primate cytokine panel and
Luminex200 (Millipore Corp., Billerica, MA).
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Histological examination
After autopsy, lung tissue samples were fixed with 10%
formalin, and embedded in paraffin. Sections were stained with
hematoxylin and eosin (H&E). Influenza virus nucleoprotein
(NP) was stained with anti-NP antibody, HB65, after treatment
of sections with pronase [62]. After incubation with anti-mouse
immunoglobulin antibody conjugated with horseradish
peroxidase, NP was detected with diaminobentidin (Nichirei
Bioscience Inc., Tokyo, Japan).
Supporting Information
Figure S1.  Flow cytometric analysis of peripheral blood
cells in immunosuppressed macaques. Cynomolgus
macaques were administered CP and CA as indicated in Table
1. Figure S1 A and B show results of the low and high dose
regimens, respectively. Blood was collected on the indicated
days after immunosuppression. Top row: dot plots of FSC and
SSC. Blue: R1 (low FSC/low SSC, lymphocytes), orange: R2
(high FSC/low SSC, mainly monocytes), red: R3 (high FSC/
high SSC, granulocytes). Second row: dot plots of CD4 and
CD8 gated on R1 cells. Third row: dot plots of CD14 and CD20
gated on R1. Bottom row: dot plots of CD14 and CD20 gated
on R2.
(TIF)
Figure S2.  Body temperature after immunosuppression
and virus infection. Cynomolgus macaques were
administered a high dose of CP and CA as shown in Table 2
(blue lines, immunosuppression). Control macaques were
administered saline (red lines, immunocompetent). Seasonal
influenza virus A/Yokohama/91/2007 (H1N1) (left, YOK91) or
pandemic influenza virus A/Narita/1/2009 (H1N1) (right, NRT1)
was inoculated into the nostrils, oral cavity, and trachea of
macaques on day 0 (red arrowheads). Body temperature of
macaques was recorded using telemetry transmitters and a
computer. Body temperature of one macaque, N6, with
immunosuppression and infection with NRT1 was not recorded
due to battery power shortage.
(TIF)
Figure S3.  Blood cell populations in immunosuppressed
macaques infected with influenza virus. Macaques were
administered CP and CA from day -7 to day 0 and then
inoculated with influenza virus YOK91, Y1-Y6, or NRT1, N1-
N6, on day 0. Blood was collected on the indicated days. Blood
cells were stained with fluorescence-conjugated antibodies
specific for CD4, CD8, CD14, and CD20. The concentration of
each population was calculated using white blood cell counts
shown in Figure 2 and the percentage determined by flow
cytometric analysis. The concentrations of CD4+, CD8+, and
CD20+ cells were calculated in R1 (low FSC/low SSC) as
shown in Figure S1. The concentrations of CD14+ cells were
calculated in R2 (high FSC/low SSC). The concentrations of
granulocytes were calculated in R3 (high FSC/high SSC). The
left y-axis indicates numbers of CD4+, CD8+, CD14+, and
CD20+ cells. The right y-axis indicates numbers of
granulocytes.
(TIF)
Figure S4.  Immunohistochemical staining for influenza
virus NP in organs of immunocompetent and
immunocompromised macaques. Tissues were collected as
described in the legend for Figure 4 and stained with anti-
influenza virus NP antibody. (A) Lung of a control macaque
without immunosuppression and virus infection. No
inflammation and NP-positive cells were observed. (B) Lung of
a macaque infected with YOK91 without immunosuppression
(Y3). (C) Lung of a macaque infected with YOK91 with
immunosuppression (Y4). (D) Bronchiole in the lung of a
macaque infected with NRT1 without immunosuppression (N1).
(E) Lung, (F) cerebellum, (G) descending colon, (H) urinary
bladder of a macaque infected with NRT1 with
immunosuppression. Bars in microscopic photos indicate 50
µm.
(TIF)
Table S1.  Clinical scoring used in this study. Animals were
monitored every day during the study to be clinically scored.
Animals would be euthanized if their clinical scores reached 15
(a humane endpoint).
(DOCX)
Acknowledgements
We thank Drs. Takato Odagiri and Chiharu Kawakami for
providing viruses, Dr. Michinori Kohara for providing antibody,
and Drs. Takahiro Nakagawa and Ikuo Kawamoto for animal
care.
Author Contributions
Conceived and designed the experiments: YI H. Ishigaki KO.
Performed the experiments: VLP MN YI H. Ishigaki MK MA H.
Ishida NK SS MO. Analyzed the data: VLP MN YI YS HK KO.
Contributed reagents/materials/analysis tools: SS MO YS HT
SN HK. Wrote the manuscript: VLP MN YI KO.
References
1. Writing committee of the WHO consultation on clinical aspects of
pandemic (H1N1) 2009 influenza (2009) Clinical aspects of pandemic
2009 influenza A (H1N1) virus infection. N Engl J Med 362 (1708-1719)
2. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y et al. (2009) In vitro
and in vivo characterization of new swine-origin H1N1 influenza
viruses. Nature 460: 1021-1025. PubMed: 19672242.
3. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ et al.
(2009) Pathogenesis and transmission of swine-origin 2009 A(H1N1)
influenza virus in ferrets. Science 325: 481-483. PubMed: 19574348.
4. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C et al.
(2009) Transmission and pathogenesis of swine-origin 2009 A(H1N1)
influenza viruses in ferrets and mice. Science 325: 484-487. PubMed:
19574347.
5. Herfst S, van den Brand JM, Schrauwen EJ, de Wit E, Munster VJ et al.
(2010) Pandemic 2009 H1N1 influenza virus causes diffuse alveolar
damage in cynomolgus macaques. Vet Pathol 47: 1040-1047. doi:
10.1177/0300985810374836. PubMed: 20647595.
Influenza Infection in Immunosuppressed Macaques
PLOS ONE | www.plosone.org 11 September 2013 | Volume 8 | Issue 9 | e75910
6. Almansa R, Bermejo-Martín JF, de Lejarazu Leonardo RO (2012)
Immunopathogenesis of 2009 pandemic influenza. Enferm Infecc
Microbiol Clin 30 Suppl 4: 18-24. doi:10.1016/j.eimc.2011.07.013.
PubMed: 23116788.
7. Viasus D, Antón A, Pumarola T, Carratalà J (2012) Influenza
A(H1N1)pdm09: beyond the pandemic. Enferm Infecc Microbiol Clin 30
Suppl 4: 54-57. doi:10.1016/S0213-005X(12)70106-4. PubMed:
23116794.
8. Morlighem JE, Aoki S, Kishima M, Hanami M, Ogawa C et al. (2011)
Mutation analysis of 2009 pandemic influenza A(H1N1) viruses
collected in Japan during the peak phase of the pandemic. PLOS ONE
6: e18956. doi:10.1371/journal.pone.0018956. PubMed: 21572517.
9. Kao CL, Chan TC, Tsai CH, Chu KY, Chuang SF et al. (2012) Emerged
HA and NA mutants of the pandemic influenza H1N1 viruses with
increasing epidemiological significance in Taipei and Kaohsiung,
Taiwan, 2009-10. PLOS ONE 7: e31162. doi:10.1371/journal.pone.
0031162. PubMed: 22328930.
10. de la Rosa-Zamboni D, Vázquez-Pérez JA, Avila-Ríos S, Carranco-
Arenas AP, Ormsby CE et al. (2012) Molecular characterization of the
predominant influenza A(H1N1)pdm09 virus in Mexico, December
2011-February 2012. PLOS ONE 7: e50116. doi:10.1371/journal.pone.
0050116. PubMed: 23209653.
11. Makkoch J, Suwannakarn K, Payungporn S, Prachayangprecha S,
Cheiocharnsin T et al. (2012) Whole genome characterization,
phylogenetic and genome signature analysis of human pandemic H1N1
virus in Thailand, 2009-2012. PLOS ONE 7: e51275. doi:10.1371/
journal.pone.0051275. PubMed: 23251479.
12. Green LC, Didier PJ, Bowers LC, Didier ES (2004) Natural and
experimental infection of immunocompromised rhesus macaques
(Macaca mulatta) with the microsporidian Enterocytozoon bieneusi
genotype D. Microbes Infect 6: 996-1002. doi:10.1016/j.micinf.
2004.05.012. PubMed: 15345231.
13. Wumba R, Longo-Mbenza B, Menotti J, Mandina M, Kintoki F et al.
(2012) Epidemiology, clinical, immune, and molecular profiles of
microsporidiosis and Cryptosporidiosis among HIV/AIDS patients. Int J
Gen Med 5: 603-611. PubMed: 22924007.
14. Kolappaswamy K, Shipley ST, Tatarov II, DeTolla LJ (2008) Methicillin-
resistant Staphylococcus non-aureus infection in an irradiated rhesus
macaque (Macaca mulatta). J Am Assoc Lab Anim Sci 47: 64-67.
PubMed: 18459716.
15. Siberry GK, Frederick T, Emmanuel P, Paul ME, Bohannon B et al.
(2012) Methicillin-resistant Staphylococcus aureus infections in human
immunodeficiency virus-infected children and adolescents. AIDS Res
Treat, 2012: 627974. PubMed: 23008761
16. Schröder C, Pfeiffer S, Wu G, Azimzadeh AM, Aber A et al. (2006)
Simian parvovirus infection in cynomolgus monkey heart transplant
recipients causes death related to severe anemia. Transplantation 81:
1165-1170. doi:10.1097/01.tp.0000203170.77195.e4. PubMed:
16641603.
17. Rerolle JP, Morelon E, Helal I, Peraldi MN, Mamzer-Bruneel MF et al.
(2004) Parvovirus B19-related anaemia after renal transplantation.
Scand J Infect Dis 36: 513-516. doi:10.1080/00365540410020244.
PubMed: 15307588.
18. Chernak E, Dubin G, Henry D, Naides SJ, Hodinka RL et al. (1995)
Infection due to parvovirus B19 in patients infected with human
immunodeficiency virus. Clin Infect Dis 20: 170-173. doi:10.1093/
clinids/20.1.170. PubMed: 7727646.
19. Lednicky JA, Arrington AS, Stewart AR, Dai XM, Wong C et al. (1998)
Natural isolates of simian virus 40 from immunocompromised monkeys
display extensive genetic heterogeneity: new implications for
polyomavirus disease. J Virol 72: 3980-3990. PubMed: 9557685.
20. Tan CS, Dezube BJ, Bhargava P, Autissier P, Wüthrich C et al. (2009)
Detection of JC virus DNA and proteins in the bone marrow of HIV-
positive and HIV-negative patients: implications for viral latency and
neurotropic transformation. J Infect Dis 199: 881-888. doi:
10.1086/597117. PubMed: 19434914.
21. Ohtaki S, Kodama H, Hondo R, Kurata T (1986) Activation of
cytomegalovirus infection in immunosuppressed cynomolgus monkeys
inoculated with varicella-zoster virus. Acta Pathol Jpn 36: 1537-1552.
PubMed: 3026140.
22. Hurd J, Heath RB (1975) Effect of cyclophosphamide on infections in
mice caused by virulent and avirulent strains of influenza virus. Infect
Immun 11: 886-889. PubMed: 1168172.
23. Schuurman HJ, Smith HT, Cozzi E (2005) Tolerability of
cyclosphosphamide and methotrexate induction immunosuppression in
nonhuman primates. Toxicology 213: 1-12. doi:10.1016/j.tox.
2005.03.017. PubMed: 15970369.
24. Sogawa H, Boskovic S, Nadazdin O, Abrahamian G, Colvin RB et al.
(2008) Limited efficacy and unacceptable toxicity of cyclophosphamide
for the induction of mixed chimerism and renal allograft tolerance in
cynomolgus monkeys. Transplantation 86: 615-619. doi:10.1097/01.tp.
0000330808.36393.93. PubMed: 18724233.
25. Buss J, Essig E, Osei K, Brodsky S, Hadley G et al. (2011) Steroid-free
maintenance of islet allografts using mycophenolate mofetil and
cyclosporine in the non-human primate. Ann Transplant 16: 88-97.
PubMed: 21716191.
26. Solbach W, Lange CE, Rollinghoff M, Wagner H (1984) Growth,
interleukin-2 production, and responsiveness to IL-2 in T4-positive T
Lymphocyte populations from malignant cutaneous T cell lymphoma
(Sezary’s syndrome): the effect of cyclosporin A. Blood 64: 1022-1027.
PubMed: 6237693.
27. Masri MA (2003) The mosaic of immunosuppressive drugs. Mol
Immunol 39: 1073-1077. doi:10.1016/S0161-5890(03)00075-0.
PubMed: 12835079.
28. Chan MC, Chan RW, Yu WC, Ho CC, Chui WH et al. (2009) Influenza
H5N1 virus infection of polarized human alveolar epithelial cells and
lung microvascular endothelial cells. Respir Res 10: 102. doi:
10.1186/1465-9921-10-102. PubMed: 19874627.
29. Nelli RK, Dunham SP, Kuchipudi SV, White GA, Baquero-Perez B et al.
(2012) Mammalian innate resistance to highly pathogenic avian
influenza H5N1 virus infection is mediated through reduced
proinflammation and infectious virus release. J Virol 86: 9201-9210.
doi:10.1128/JVI.00244-12. PubMed: 22718824.
30. Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le M et al.
(2011) Cytokine production by primary human macrophages infected
with highly pathogenic H5N1 or pandemic H1N1 2009 influenza
viruses. J Gen Virol 92: 1428-1434. doi:10.1099/vir.0.030346-0.
PubMed: 21367984.
31. Nakajima N, Van Tin N, Sato Y, Thach HN, Katano H et al. (2012)
Pathological study of archival lung tissues from five fatal cases of avian
H5N1 influenza in Vietnam. Mod Pathol 26: 357-369. PubMed:
23174938.
32. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W et al. (1998) Local
and systemic cytokine responses during experimental human influenza
A virus infection. Relation to symptom formation and host defense. J
Clin Invest 101: 643-649. doi:10.1172/JCI1355. PubMed: 9449698.
33. Kozak W, Kluger MJ, Soszynski D, Conn CA, Rudolph K et al. (1998)
IL-6 and IL-1β in fever. Studies using cytokine-deficient (knockout)
mice. Ann N Y Acad Sci 856: 33-47. doi:10.1111/j.
1749-6632.1998.tb08310.x. PubMed: 9917862.
34. Van Reeth K (2000) Cytokines in the pathogenesis of influenza. Vet
Microbiol 74: 109-116. doi:10.1016/S0378-1135(00)00171-1.
35. Nakae H, Endo S, Inoue Y, Fujino Y, Wakabayashi G et al. (2003)
Matrix metalloproteinase-1 and cytokines in patients with acute
pancreatitis. Pancreas 26: 134-138. doi:
10.1097/00006676-200303000-00008.
36. Carlson CM, Turpin EA, Moser LA, O’Brien KB, Cline TD et al. (2010)
Transforming growth factor-β: activation by neuraminidase and role in
highly pathogenic H5N1 influenza pathogenesis. PLOS Pathog 6:
e1001136.
37. Liu X, Zhao Z, Li Z, Xu C, Sun L et al. (2012) Cyclosporin A inhibits the
influenza virus replication through cyclophilin A-dependent and -
independent pathways. PLOS ONE 7: e37277. doi:10.1371/
journal.pone.0037277.
38. Cook RM (1983) Activity of cyclosporin A in experimental influenza
virus infection in mice. Agents Actions 13: 98-100. doi:10.1007/
BF01994290.
39. Schiltknecht E, Ada GL (1985) In vivo effects of cyclosporine on
influenza A virus-infected mice. Cell Immunol 91: 227-239. doi:
10.1016/0008-8749(85)90046-2.
40. Singer SH, Noguchi P, Kirschstein RL (1972) Respiratory diseases in
cyclophosphamide-treated mice II. Decreased virulence of PR8
influenza virus. Infect Immun 5: 957-960..
41. Cooksley CD, Avritscher EB, Bekele BN, Rolston KV, Geraci JM et al.
(2005) Epidemiology and outcomes of serious influenza-related
infections in the cancer population. Cancer 104: 618-628. doi:10.1002/
cncr.21203.
42. Cordero E, Aydillo T, Farinas MC, Pano-Pardo JR, Pachon J et al.
(2012) Immunosuppressed patients with pandemic influenza A 2009
(H1N1) virus infection. Eur J Clin Microbiol Infect Dis 31: 547-556. doi:
10.1007/s10096-011-1346-3.
43. Kunisaki KM, Janoff EN (2009) Influenza in immunosuppressed
populations: a review of infection frequency, morbidity, mortality, and
vaccine responses. Lancet Infect Dis 9: 493-504. doi:10.1016/
S1473-3099(09)70175-6.
44. Meerveld-Eggink A, de Weerdt O, van der Velden AM, Los M, van der
Velden AW et al. (2011) Response to influenza virus vaccination during
Influenza Infection in Immunosuppressed Macaques
PLOS ONE | www.plosone.org 12 September 2013 | Volume 8 | Issue 9 | e75910
chemotherapy in patients with breast cancer. Ann Oncol 22:
2031-2035. doi:10.1093/annonc/mdq728.
45. Huang KL, Armstrong JA, Ho M (1983) Antibody response after
influenza immunization in renal transplant patients receiving
cyclosporin A or azathioprine. Infect Immun 40: 421-424.
46. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Schilz RJ et al.
(2001) The humoral immune response to influenza vaccination in lung
transplant patients. Eur Respir J 18: 971-976. doi:
10.1183/09031936.01.00215201. PubMed: 11829104.
47. Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, Beyer WE, Tilanus
HW (2000) Efficacy of influenza vaccination in adult liver transplant
recipients. J Med Virol 61: 85-93. doi:10.1002/
(SICI)1096-9071(200005)61:1.
48. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG (2006)
Recovery of drug-resistant influenza virus from immunocompromised
patients: a case series. J Infect Dis 193: 760-764. doi:10.1086/500465.
PubMed: 16479508.
49. van der Vries E, Stelma FF, Boucher CA (2010) Emergence of a
multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med
363: 1381-1382. doi:10.1056/NEJMc1003749. PubMed: 20879894.
50. Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C et al. (2007)
Differential role of TLR- and RLR-signaling in the immune responses to
influenza A virus infection and vaccination. J Immunol 179: 4711-4720.
51. Nilsberth C, Elander L, Hamzic N, Norell M, Lonn J et al. (2009) The
role of interleukin-6 in lipopolysaccharide-induced fever by mechanisms
independent of prostaglandin E2. Endocrinology 150: 1850-1860. doi:
10.1210/en.2008-0806. PubMed: 19022895.
52. Brun-Buisson C, Richard JC, Mercat A, Thiébaut AC, Brochard L
(2011) Early corticosteroids in severe influenza A/H1N1 pneumonia
and acute respiratory distress syndrome. Am J Respir Crit Care Med
183: 1200-1206. doi:10.1164/rccm.201101-0135OC. PubMed:
21471082.
53. Xu T, Qiao J, Zhao L, He G, Li K et al. (2009) Effect of dexamethasone
on acute respiratory distress syndrome induced by the H5N1 virus in
mice. Eur Respir J 33: 852-860. doi:10.1183/09031936.00130507.
54. Confalonieri M, Kodric M, Santagiuliana M, Longo C, Biolo M et al.
(2012) To use or not to use corticosteroids for pneumonia? A clinician’s
perspective. Monaldi Arch Chest Dis 77: 94-101.
55. Evseenko VA, Bukin EK, Zaykovskaya AV, Sharshov KA, Ternovoi VA
et al. (2007) Experimental infection of H5N1 HPAI in BALB/c mice. Virol
J 4: 77. doi:10.1186/1743-422X-4-77. PubMed: 17662125.
56. Cilloniz C, Shinya K, Peng X, Korth MJ, Proll SC et al. (2009) Lethal
influenza virus infection in macaques is associated with early
dysregulation of inflammatory related genes. PLOS Pathog 5:
e1000604.
57. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP
et al. (2009) Early and sustained innate immune response defines
pathology and death in nonhuman primates infected by highly
pathogenic influenza virus. Proc Natl Acad Sci U S A 106: 3455-3460.
doi:10.1073/pnas.0813234106. PubMed: 19218453.
58. Kawakami C, Obuchi M, Saikusa M, Noguchi Y, Ujike M et al. (2009)
Isolation of oseltamivir-resistant influenza A/H1N1 virus of different
origins in Yokohama City, Japan, during the 2007-2008 influenza
season. Jpn J Infect Dis 62: 83-86.
59. Shiino T, Okabe N, Yasui Y, Sunagawa T, Ujike M et al. (2010)
Molecular evolutionary analysis of the influenza A(H1N1)pdm, May-
September, 2009: temporal and spatial spreading profile of the viruses
in Japan. PLOS ONE 5: e11057. doi:10.1371/journal.pone.0011057.
60. Arikata M, Itoh Y, Okamatsu M, Maeda T, Shiina T et al. (2012)
Memory immune responses against pandemic (H1N1) 2009 influenza
virus induced by a whole particle vaccine in cynomolgus monkeys
carrying Mafa-A1*052:02. PLOS ONE 7: e37220. doi:10.1371/
journal.pone.0037220.
61. Itoh Y, Ozaki H, Tsuchiya H, Okamoto K, Torii R et al. (2008) A vaccine
prepared from a non-pathogenic H5N1 avian influenza virus strain
confers protective immunity against highly pathogenic avian influenza
virus infection in cynomolgus macaques. Vaccine 26: 562-572. doi:
10.1016/j.vaccine.2007.11.031. PubMed: 18164788.
62. Nicholls JM, Wong LP, Chan RW, Poon LL, So LK et al. (2012)
Detection of highly pathogenic influenza and pandemic influenza virus
in formalin fixed tissues by immunohistochemical methods. J Virol
Methods 179: 409-413. doi:10.1016/j.jviromet.2011.11.006.
Influenza Infection in Immunosuppressed Macaques
PLOS ONE | www.plosone.org 13 September 2013 | Volume 8 | Issue 9 | e75910
